0001193125-21-331379.txt : 20211116 0001193125-21-331379.hdr.sgml : 20211116 20211116172059 ACCESSION NUMBER: 0001193125-21-331379 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20211116 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211116 DATE AS OF CHANGE: 20211116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENET HEALTHCARE CORP CENTRAL INDEX KEY: 0000070318 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 952557091 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07293 FILM NUMBER: 211417381 BUSINESS ADDRESS: STREET 1: 14201 DALLAS PARKWAY CITY: DALLAS STATE: TX ZIP: 75254 BUSINESS PHONE: 469-893-2200 MAIL ADDRESS: STREET 1: 14201 DALLAS PARKWAY CITY: DALLAS STATE: TX ZIP: 75254 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL MEDICAL ENTERPRISES INC /NV/ DATE OF NAME CHANGE: 19920703 8-K 1 d260541d8k.htm 8-K 8-K
TENET HEALTHCARE CORP false 0000070318 0000070318 2021-11-16 2021-11-16 0000070318 us-gaap:CommonStockMember 2021-11-16 2021-11-16 0000070318 us-gaap:SeniorNotesMember 2021-11-16 2021-11-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: November 16, 2021

(Date of earliest event reported)

 

 

TENET HEALTHCARE CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   1-7293   95-2557091
(State of Incorporation)  

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

14201 Dallas Parkway
Dallas, Texas 75254
(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.05 par value   THC   New York Stock Exchange
6.875% Senior Notes due 2031   THC31   New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


The information in Item 7.01 of this Current Report on Form 8-K and the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.

 

Item 7.01.

Regulation FD Disclosure.

On November 16, 2021, Tenet Healthcare Corporation (the “Company”) issued a press release announcing the commencement of a private placement offering of $1.450 billion in aggregate principal amount of its senior secured first lien notes due 2030. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated herein by reference.

Additionally, on November 16, 2021, the Company issued a press release announcing the pricing of $1.450 billion in aggregate principal amount of its 4.375% senior secured first lien notes due 2030 (the “notes”). The closing of the sale of the notes is expected to occur on December 1, 2021, and is subject to customary closing conditions. A copy of the press release is being furnished as Exhibit 99.2 attached hereto and is incorporated herein by reference.

The Company intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to finance the acquisition of Surgical Center Development #3, LLC and Surgical Center Development #4, LLC’s ownership interest in a portfolio of 92 ambulatory surgery centers and certain other related assets, with any remainder for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures. If the acquisition is not completed, the Company intends to use the net proceeds for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures.

The notes will be guaranteed by certain of the Company’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of the Company’s subsidiaries. The notes will be effectively senior to the Company’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.

 

Item 9.01.

Financial Statements and Exhibits.

 

  (d)

Exhibits.

 

Exhibit No.

  

Description

99.1    Press Release issued by the Company on November 16, 2021, announcing the commencement of the offering of the notes.
99.2    Press Release issued by the Company on November 16, 2021, announcing the pricing of the notes.
104    Cover Page Interactive Data File (embedded within the inline XBRL document).

 

1


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TENET HEALTHCARE CORPORATION
By:  

/s/ Thomas Arnst

  Name: Thomas Arnst
  Title: Executive Vice President, Chief Administrative Officer and General Counsel

Date: November 16, 2021

EX-99.1 2 d260541dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Tenet Announces $1.450 Billion Private Offering of Senior Secured Notes

DALLAS – Nov. 16, 2021 – Tenet Healthcare Corporation (NYSE: THC) today announced a private placement offering of $1.450 billion in aggregate principal amount of newly issued senior secured first lien notes maturing in 2030 (the “notes”). Completion of the offering is subject to, among other things, pricing and standard closing and market conditions.

Tenet intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to finance the acquisition of Surgical Center Development #3, LLC and Surgical Center Development #4, LLC’s ownership interest in a portfolio of 92 ambulatory surgery centers and certain other related assets, with any remainder for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures. If the acquisition is not completed, Tenet intends to use the net proceeds for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures.

The notes will be guaranteed by certain of Tenet’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of Tenet’s subsidiaries. The notes will be effectively senior to Tenet’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.

The notes to be offered will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other state securities laws. As a result, they may not be offered or sold in the United States or to any U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the notes will be offered only to persons reasonably believed to be “qualified institutional buyers” under Rule 144A of the Securities Act or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. A confidential offering memorandum for the notes will be made available to such eligible persons. The offering will be conducted in accordance with the terms and subject to the conditions set forth in such offering memorandum.


This news release is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Cautionary Statement

This release contains “forward-looking statements”—that is, statements that relate to future, not past, events. In this context, forward-looking statements often address Tenet’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regard to developments related to COVID-19. Particular uncertainties that could cause Tenet’s actual results to be materially different than those expressed in Tenet’s forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2020, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas with more than 100,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 60 hospitals and approximately 460 other healthcare facilities, including surgical hospitals, ambulatory surgery centers and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve.

###

 

Investor Contact:

Regina Nethery

469-893-2387

regina.nethery@tenethealth.com

  

Media Contact:

Lesley Bogdanow

469-893-2640

mediarelations@tenethealth.com

EX-99.2 3 d260541dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Tenet Announces Pricing of its $1.450 Billion Private Offering of Senior Secured Notes

DALLAS – Nov. 16, 2021 – Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.450 billion in aggregate principal amount of senior secured first lien notes due on January 15, 2030, which will bear interest at a rate of 4.375% per annum (the “notes”). Completion of the notes offering is expected to occur on December 1, 2021, and is subject to, among other things, standard closing and market conditions.

Tenet intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to finance the acquisition of Surgical Center Development #3, LLC and Surgical Center Development #4, LLC’s ownership interest in a portfolio of 92 ambulatory surgery centers and certain other related assets, with any remainder for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures. If the acquisition is not completed, Tenet intends to use the net proceeds for general corporate purposes, which may include, without limitation, repayment and refinancing of other debt, cash on balance sheet, working capital and capital expenditures.

The notes will be guaranteed by certain of Tenet’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of Tenet’s subsidiaries. The notes will be effectively senior to Tenet’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings.

The notes to be offered will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other state securities laws. As a result, they may not be offered or sold in the United States or to any U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the notes will be offered only to persons reasonably believed to be “qualified institutional buyers” under Rule 144A of the Securities Act or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. A confidential offering memorandum for the notes will be made available to such eligible persons. The offering will be conducted in accordance with the terms and subject to the conditions set forth in such offering memorandum.


This news release is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Cautionary Statement

This release contains “forward-looking statements”—that is, statements that relate to future, not past, events. In this context, forward-looking statements often address Tenet’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regard to developments related to COVID-19. Particular uncertainties that could cause Tenet’s actual results to be materially different than those expressed in Tenet’s forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2020, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas with more than 100,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 60 hospitals and approximately 460 other healthcare facilities, including surgical hospitals, ambulatory surgery centers and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve.

###

 

Investor Contact:

Regina Nethery

469-893-2387

regina.nethery@tenethealth.com

  

Media Contact:

Lesley Bogdanow

469-893-2640

mediarelations@tenethealth.com

EX-101.SCH 4 thc-20211116.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 thc-20211116_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 thc-20211116_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Senior Notes [Member] Senior Notes [Member] EX-101.PRE 7 thc-20211116_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g260541g1115180800348.jpg GRAPHIC begin 644 g260541g1115180800348.jpg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end GRAPHIC 9 g260541g1115180836020.jpg GRAPHIC begin 644 g260541g1115180836020.jpg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end XML 10 d260541d8k_htm.xml IDEA: XBRL DOCUMENT 0000070318 2021-11-16 2021-11-16 0000070318 us-gaap:CommonStockMember 2021-11-16 2021-11-16 0000070318 us-gaap:SeniorNotesMember 2021-11-16 2021-11-16 TENET HEALTHCARE CORP false 0000070318 8-K 2021-11-16 NV 1-7293 95-2557091 14201 Dallas Parkway Dallas TX 75254 (469) 893-2200 Common stock, $0.05 par value THC NYSE 6.875% Senior Notes due 2031 THC31 NYSE false false false false false XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 16, 2021
Document And Entity Information [Line Items]  
Entity Registrant Name TENET HEALTHCARE CORP
Amendment Flag false
Entity Central Index Key 0000070318
Document Type 8-K
Document Period End Date Nov. 16, 2021
Entity Incorporation State Country Code NV
Entity File Number 1-7293
Entity Tax Identification Number 95-2557091
Entity Address, Address Line One 14201 Dallas Parkway
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75254
City Area Code (469)
Local Phone Number 893-2200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, $0.05 par value
Trading Symbol THC
Security Exchange Name NYSE
Senior Notes [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 6.875% Senior Notes due 2031
Trading Symbol THC31
Security Exchange Name NYSE
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d260541d8k.htm d260541dex991.htm d260541dex992.htm thc-20211116.xsd thc-20211116_def.xml thc-20211116_lab.xml thc-20211116_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d260541d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "thc-20211116_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d260541d8k.htm" ] }, "labelLink": { "local": [ "thc-20211116_lab.xml" ] }, "presentationLink": { "local": [ "thc-20211116_pre.xml" ] }, "schema": { "local": [ "thc-20211116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 2, "nsprefix": "thc", "nsuri": "http://www.tenethealth.com/20211116", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d260541d8k.htm", "contextRef": "duration_2021-11-16_to_2021-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d260541d8k.htm", "contextRef": "duration_2021-11-16_to_2021-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "thc_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.tenethealth.com/20211116", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "thc_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.tenethealth.com/20211116", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.tenethealth.com//20211116/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-21-331379-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-331379-xbrl.zip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end